港股详情

本页面由TTMF Limited提供服务

百利天恒待上市

成交量：- -

成交额：- -

市值：- -

市盈率：- -

高：- -

开：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：4.22亿

香港流通股本：4.22亿

量比：- -

换手率：- -

股息：- -

股息率：- -

净资产收益率：-14.94%

总资产收益率：-5.41%

市净率：0.00

市盈率(LYR):- -

市销率: 0.00

1

开始申购

11/07

2

申购截止

11/12 09:30

3

公布中签

11/13

4

暗盘

12/31 16:15 - 18:30

5

挂牌上市

11/17

总览公司新闻资讯公告

价格范围

347.50 ~ 389.00 HKD

发行价

- -

发行量

863.43万

预计市值

1,464.74亿 ~ 1,639.67亿 HKD

最低申购数量

100

承销商

高盛(亚洲)有限责任公司

查看招股说明书

新闻资讯

百利天恒、正大天晴、康宁杰瑞等一批国内创新药企掀起双抗ADC新浪潮

刷新创新药出海纪录！百利天恒拿下ADC单笔最高里程碑付款

创新药阶层跨越，只需一款大药

百利天恒连放两个大招

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/02615"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02615","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02615\",,,,,undefined,":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1764921600000,"preClose":0,"halted":7,"volume":0,"delay":0,"floatShares":421508117,"shares":421508117,"eps":0,"marketStatus":"待上市","change":0,"latestTime":"12-05 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":4102450200000},"marketStatusCode":8,"adr":0,"listingDate":4102416000000,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1764898200000,1764907200000],[1764910800000,1764921600000]],"volumeRatio":0,"ipoDetail":{"name":"百利天恒","exchange":"SEHK","listingDate":"2100-01-01","sharesOutstanding":421508117,"sharesFloat":421508117,"offerAmount":8634300,"priceRange":"347.500 - 389.000","market":"HK","openProspectusDate":"2025-11-07","openProspectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1107/2025110700014_c.pdf","purchaseBeginDate":"2025-11-07","purchaseEndDate":"2025-11-12","winningDate":"2025-11-14","currency":"HKD","minPurchaseQuantity":100,"peRate":39.25,"use":"1、约60.0%或1,810.5百万港元将用于拨付于中国内地以外地区的生物候选药物的研发活动；\n2、约30.0%或905.2百万港元将用于建立全球供应链，主要为在中国内地以外地区的生物候选药物的新生产设施的建设或潜在收购机会提供资金；\n3、约10.0%或301.7百万港元将用于拨付在中国内地以外业务的营运资金及其他一般公司用途。","industryId":"204005","industryName":"医疗保健","business":"公司是一家具备早期研发、临床开发、生产及商业化能力的综合医疗企业集团。","subscribed":19.93,"marketCap":146474000000,"minimumCapital":39292.31,"overAllotment":false,"lotSize":100,"issueOpenRate":0.1,"subscribeGear":"100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,15000,20000,25000,30000,35000,40000,45000,50000,60000,70000,80000,90000,100000,150000,200000,300000,431700"},"greyMarketDetail":{"greyDate":"2099-12-31","greyDateTimestamp":4102329600000,"greyOpeningTime":4102388100000,"greyClosingTime":4102396200000,"showGreyQuote":false,"openProspectusDate":"2025-11-07","listingDate":"2100-01-01"},"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":363.95,"timestamp":1764918000000,"preClose":365.03,"halted":0,"volume":656100,"delay":0,"premium":"-100.00"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02615\",,,,,undefined,":{"symbol":"02615","floatShares":421508117,"roa":"-5.41%","roe":"-14.94%","lyrEps":0,"shares":421508117,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"0.00","psRate":"0.00","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hktrade.skytigris.com/ipos/general/02615\",,undefined,":{"id":9063,"type":"COMMON","ipoName":"02615-IPO","symbol":"02615","companyName":"百利天恆","market":"HK","currency":"HKD","status":"CANCELLED","underwriter":"高盛(亚洲)有限责任公司","lotSize":100,"minQty":100,"expectedOfferingSize":8634300,"openingDate":1762479000000,"closingDate":1762911000000,"commonClosingDate":1762911000000,"allotmentDate":1762963200000,"listDate":1763308800000,"marginable":true,"latestPrice":389,"minPrice":347.5,"maxPrice":389,"prospectusUrl":"https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1107/2025110700014_c.pdf","allowedQuantities":[100,200,300,400,500,600,700,800,900,1000,1500,2000,2500,3000,3500,4000,4500,5000,6000,7000,8000,9000,10000,15000,20000,25000,30000,35000,40000,45000,50000,60000,70000,80000,90000,100000,150000,200000,300000,431700],"recommend":false,"isHint":false,"interestStartDate":1762876800000,"interestEndDate":1762876800000,"delayAllocate":false,"isSupportGreyMarket":true,"greyMarketTradeDate":1763108100000,"transactionRate":0.010085,"gstFeeRate":0,"rank":0,"subscribed":false,"signed":false,"financingInfos":[],"financingNotifyEnabled":false,"financingNotifySubscribed":false,"subscriptionMethods":[],"latestClosingDate":1765099298993,"subscribedFinanceRatio":19.93,"subscribedRatio":19.93,"forecastRatio":24.31,"raiseMoney":335900000,"totalMargin":6694640000,"quoteInfoUpdatedAt":1765070909370,"prospectusUpdatedAt":1762928848000,"forecastMarketValue":155220364085.25,"minForecastMarketValue":146474070657.5,"maxForecastMarketValue":163966657513,"sharesOutstanding":421508117,"business":"公司是一家具备早期研发、临床开发、生产及商业化能力的综合医疗企业集团。","greyOpeningTime":4102388100000,"greyClosingTime":4102396200000,"tradable":false},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02615\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2588619883","title":"百利天恒、正大天晴、康宁杰瑞等一批国内创新药企掀起双抗ADC新浪潮","url":"https://stock-news.laohu8.com/highlight/detail?id=2588619883","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588619883?lang=zh_cn&edition=fundamental","pubTime":"2025-12-04 16:00","pubTimestamp":1764835212,"startTime":"0","endTime":"0","summary":"当前，双抗ADC凭借双重优势，成为药企差异化竞争的核心赛场。而中国双抗ADC药物领域，百利天恒、正大天晴、康宁杰瑞等正在不断实现跨越。这是该药物继7月份针对HER2阳性乳腺癌适应症后，第2次获得突破性治疗认定。目前，正大天晴已登记开展9项TQB2102临床研究，覆盖乳腺癌、结直肠癌、肺癌、胆管癌和胃癌等多种适应症。此外，康宁杰瑞的双抗ADC药物JSKN-003同样表现亮眼，目前该产品已顺利进入临床III期阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204160434952a6b60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204160434952a6b60&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2097828714.EUR","BK1589","BK1574","91194","LU2097828557.USD","HK0000165453.HKD","LU2097828474.EUR","LU2097828805.USD","01276","LU2242644610.SGD","09966","LU2488822045.USD","01801","LU0455707207.USD","LU2097828631.EUR","06978","BK1161","LU2328871848.SGD","LU1969619763.USD","LU0502904849.HKD","BK1583","02615"],"gpt_icon":0},{"id":"2588201140","title":"刷新创新药出海纪录！百利天恒拿下ADC单笔最高里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2588201140","media":"药财社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588201140?lang=zh_cn&edition=fundamental","pubTime":"2025-12-03 19:02","pubTimestamp":1764759725,"startTime":"0","endTime":"0","summary":"加上2023年12月合作签署时支付的8亿美元首付款，这条尚未上市的管线已为百利天恒带来累计10.5亿美元现金。▲关注药财社聚焦医药界▲里程碑现金的含金量：从“讲故事”到“可复验的进度”此次2.5亿美元被市场视为中国创新药出海交易中单个ADC资产首笔里程碑付款的最高纪录。协议披露显示，百利天恒后续仍可能获得最高2.5亿美元的近期或有付款，并在开发、注册及销售里程碑上获得最高71亿美元的额外款项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203193608a7216f5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203193608a7216f5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02615","BK1574","06978","91194"],"gpt_icon":0},{"id":"2588018874","title":"创新药阶层跨越，只需一款大药","url":"https://stock-news.laohu8.com/highlight/detail?id=2588018874","media":"制药在线","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588018874?lang=zh_cn&edition=fundamental","pubTime":"2025-12-03 10:53","pubTimestamp":1764730424,"startTime":"0","endTime":"0","summary":"对于处于高速发展阶段的中国创新药企业来说，一款“大药”的意义，是如何强调都不为过的。对于百利天恒而言，iza-bren无疑是让公司有望在全球创新药行业实现阶层跃迁的一款战略性大药。作为全球首 创且唯一进入上市审批阶段的EGFR x HER3双抗ADC药物，iza-bren无疑也是百利天恒实现阶层跨越的一个绝 佳契机。与此同时，BMS的抗肿瘤药物版图中，O药的红利期正在急速消退，专利悬崖近在咫尺，这家跨国药企急需下一个能“挑大梁”的超级重磅炸弹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203105352a4c95217&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203105352a4c95217&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","06978","02615"],"gpt_icon":0},{"id":"2588018380","title":"百利天恒连放两个大招","url":"https://stock-news.laohu8.com/highlight/detail?id=2588018380","media":"药械Talks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588018380?lang=zh_cn&edition=fundamental","pubTime":"2025-12-03 09:47","pubTimestamp":1764726446,"startTime":"0","endTime":"0","summary":"短短几天时间，百利天恒连续放出两个大招。如今，凭借已在国内斩获12项适应症，特瑞普利单抗在2025年前三季度大卖近15亿元，同比增长40%。特别值得一提的是，截至2025年9月，百利天恒正在中国和美国就iza-bren开展40余项针对多种肿瘤类型的临床试验，其中正在中国开展11项不同癌种的III期临床注册研究，覆盖肺癌、乳腺癌、尿路上皮癌、食管癌和卵巢癌等多个实体瘤。如今，百利天恒的目标是成为在肿瘤治疗领域全球领先的MNC。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203103926a7206a24&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203103926a7206a24&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["91194","02615"],"gpt_icon":0}],"pageSize":4,"totalPage":21,"pageCount":1,"totalSize":82,"code":"91000000","status":"200"}]}}